September 25, 2008 – Proton therapy (a specialized type of external beam radiation therapy using protons rather than X-rays to treat cancer) decreases the risk of patients developing a secondary cancer by two-fold, compared to being treated with standard photon radiation treatment, according to a first-of-its-kind study presented Sept. 22, 2008, at the American Society for Therapeutic Radiology and Oncology’s 50th Annual Meeting in Boston.

This study contradicts recent theories that have suggested that proton radiation might actually increase — instead of decrease — the incidence of secondary cancers because of what is called scatter radiation. When proton radiation is delivered, neutrons are produced by nuclear interactions and are therefore scattered as a result.

“This study could have a substantial impact on the care of patients,” Nancy Tarbell, M.D., senior author of the study and a radiation oncologist at the Massachusetts General Hospital in Boston, said. “Since cancer patients are surviving for longer periods of time, side effects of therapy are becoming increasingly important for doctors to consider when developing treatment plans. Since this is a retrospective study, however, we will need additional studies to further prove this hypothesis.”

This study contradicts recent theories that have suggested that proton radiation might actually increase - instead of decrease - the incidence of secondary cancers because of what is called scatter radiation. When proton radiation is delivered, neutrons are produced by nuclear interactions and are therefore scattered as a result.

Photon radiation is the standard external beam radiation therapy treatment, while proton radiation is a more targeted form of external beam radiation, which delivers less radiation to bordering normal structures. During external beam radiation therapy, a beam of radiation is directed through the skin to the cancer and the immediate surrounding area in order to destroy the main tumor and any nearby cancer cells. The retrospective cohort study matched 503 patients who underwent Harvard Cyclotron proton radiation treatment with 1,591 patients treated with photon radiation therapy from the Surveillance, Epidemiology and End Results (SEER) cancer registry from 1974 to 2001. According to the study, 6.4 percent of patients who underwent proton therapy developed a secondary cancer while 12.8 percent of patients who had photon treatment developed another type of cancer.

For more information: www.rtanswers.org and www.astro.org


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Radiation Oncology

June 3, 2024 — The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details ...

Time June 03, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 30, 2024 — RaySearch Laboratories AB announced the release of the latest version of RayCare, the next generation ...

Time May 30, 2024
arrow
Subscribe Now